Lang A, Vasar E, Soosaar A, Harro J
Department of Physiology, Tartu University, Estonia.
Pharmacol Toxicol. 1992 Aug;71(2):132-8. doi: 10.1111/j.1600-0773.1992.tb00532.x.
An atypical antipsychotic drug clozapine and a selective sigma antagonist BMY 14802 were significantly less effective in the behavioural experiments (against apomorphine, d-amphetamine and MK-801), as well in the radioligand binding studies against 3H-spiperone (dopamine2-receptors) and 3H-haloperidol (sigma receptors) in the rat brain, as compared to a typical antipsychotic compound haloperidol. Contrary to haloperidol and BMY 14802, clozapine was a relatively selective antagonist of MK-801-induced motor excitation in the mouse. A nearly 3-fold lower dose of clozapine was needed to block the effect of MK-801 (6.4 mumol/kg) as compared to the action of amphetamine (17 mumol/kg). Haloperidol and clozapine, but not BMY 14802, antagonized apomorphine-induced aggressiveness in the rat. After long-term treatment (for 15 days) with BMY 14802 (10 mg/kg daily), haloperidol (0.5 mg/kg daily) and clozapine (10 mg/kg daily) the motor depressant effect of apomorphine (0.15 mg/kg) was reversed. Chronic haloperidol treatment, but not administration of BMY 14802 and clozapine, increased the number of dopamine2-receptors in the rat brain. BMY 14802 caused upregulation of sigma receptors in frontal cortex, whereas haloperidol induced the opposite change in cerebellum. Repeated treatment with clozapine significantly augmented the motor stimulating effect of MK-801 in rats. Simultaneously with a behavioural change the density of 3H-TCP binding sites in the rat forebrain was elevated after long-term treatment with clozapine, probably indicating the involvement of PCP binding sites at NMDA channel in the action of clozapine.
与典型抗精神病药物氟哌啶醇相比,非典型抗精神病药物氯氮平和选择性σ拮抗剂BMY 14802在行为实验(对抗阿扑吗啡、d-苯丙胺和MK-801)以及大鼠脑内针对3H-螺哌啶(多巴胺2受体)和3H-氟哌啶醇(σ受体)的放射性配体结合研究中效果明显较差。与氟哌啶醇和BMY 14802相反,氯氮平是小鼠中MK-801诱导的运动兴奋的相对选择性拮抗剂。与苯丙胺(17 μmol/kg)的作用相比,阻断MK-801(6.4 μmol/kg)的作用所需的氯氮平剂量低近3倍。氟哌啶醇和氯氮平,但不是BMY 14802,能拮抗阿扑吗啡诱导的大鼠攻击性。用BMY 14802(每日10 mg/kg)、氟哌啶醇(每日0.5 mg/kg)和氯氮平(每日10 mg/kg)长期治疗(15天)后,阿扑吗啡(0.15 mg/kg)的运动抑制作用被逆转。慢性氟哌啶醇治疗,但不是BMY 14802和氯氮平的给药,增加了大鼠脑内多巴胺2受体的数量。BMY 14802导致额叶皮质中σ受体上调,而氟哌啶醇在小脑中诱导相反的变化。氯氮平重复治疗显著增强了MK-801对大鼠的运动刺激作用。长期氯氮平治疗后,大鼠前脑3H-TCP结合位点的密度在行为改变的同时升高,这可能表明NMDA通道处的PCP结合位点参与了氯氮平的作用。